Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer
Conclusions:
WWOX rs11644322 represents a major predictive factor in gemcitabine-treated pancreatic cancer. Decreased WWOX expression may interfere with gemcitabine sensitivity, and allele-specific binding at rs11644332 might be a causative molecular mechanism behind the observed clinical associations.
Source: JNCI - Category: Cancer & Oncology Authors: Schirmer, M. A., Lüske, C. M., Roppel, S., Schaudinn, A., Zimmer, C., Pflüger, R., Haubrock, M., Rapp, J., Güngör, C., Bockhorn, M., Hackert, T., Hank, T., Strobel, O., Werner, J., Izbicki, J. R., Johnsen, S. A., Gaedcke, J Tags: Article Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Pancreas | Pancreatic Cancer | Statistics | Study